C-8XTIRejenevie Therapeutics
immune restoration, stem cell therapy, parabiosis
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8XTI
C-8XTIC-8XTIimmune restoration, stem cell therapy, parabiosis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rejenevie Therapeutics immune restoration, stem cell therapy, parabiosis
Rejenevie Therapeutics is a clinical-stage biotechnology company developing immune restoration treatments for age-related diseases. Its approach is based on parabiosis and a Transwell cell culture system intended to identify youthful restorative factors and improve aging stem cell and immune cell function. Its lead therapy, AR-100, is described as an autologous mobilized peripheral blood cell therapy in Phase II studies at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Rejenevie Therapeutics — Translational · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic